Future research priorities include: - Safety in Diverse Populations: Large-scale trials are needed to establish the long-term safety and efficacy of dual receptor agonists in special populations, including patients with type 1 diabetes and pregnant women
Many people experience side effects when taking this level of GLP-1 agonists
Efectos adversos graves: Aunque raros, ciertos efectos adversos graves requieren atencin inmediata: Pancreatitis aguda: Se ha reportado con agonistas GLP-1, aunque la relacin causal sigue siendo incierta
However, research showed that GLP-1 was removed from our bloodstream quickly and had a half-life of two minutes as its degraded by an enzyme called DPP4
[20] [21] When patients achieve substantial weight loss through GLP-1 therapy, the biomechanical burden on these joints decreases proportionally
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial